COVID-19 Booster + Flu Vaccine for Immunocompromised People (CO2I2 Trial)

Phase 2

Waitlist Available

Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adults (≥18 years)

Received the primary mRNA COVID-19 vaccine series (i.e., ≥3 doses)

Must not have

Contraindication to intramuscular vaccines such as bleeding disorder, severe thrombocytopenia, etc

Receiving intravenous immunoglobulins

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study covid-19 booster

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to find the best way to boost the immune response in people with weakened immune systems. They want to see if getting the COVID-19 booster shot along with the flu vaccine at the same

Who is the study for?

This trial is for people with conditions like HIV, lupus, or rheumatoid arthritis that weaken their immune system. It's also for those who've had an organ transplant. Participants should be due for a COVID-19 booster and flu shot but can't join if they have certain health issues that aren't listed here.

What is being tested?

The study tests how well the body responds to different schedules of COVID-19 boosters and flu shots in immunocompromised individuals. It checks if giving both vaccines together works as well as spacing them out, and whether getting COVID-19 boosters every 3 months is better than every 6 months.

What are the potential side effects?

Possible side effects include typical reactions to vaccines such as soreness at the injection site, fever, fatigue, headache, muscle pain. The study will monitor any other adverse effects on participants' health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have received at least 3 doses of the mRNA COVID-19 vaccine.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot receive vaccines by injection due to a bleeding disorder or very low platelet count.

Select...

I am currently receiving IV immunoglobulin therapy.

Select...

I have a genetic immune system disorder.

Select...

I am unable to understand or sign the consent form.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study covid-19 booster

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study covid-19 booster

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study covid-19 booster for reporting.